TOP ONCOLOGY CRO
EXPERTS IN CLINICAL ONCOLOGY
QUALITY ONCOLOGY TRIAL MONITORING
home blog news careers français contact
QUALITY ONCOLOGY TRIAL MANAGEMENT



The Reverse Feasibility Program™

A Novel CRO Approach to Site Selection
& Patient Recruitment

Reverse Feasibility Program for 50% faster site start-up.A revolutionary approach to feasibility assessment that accelerates study start-up by matching your protocol with the current study needs of motivated and pre-qualified North American sites.

How it works...


Oncology Clinical Trial News

Scimega launches Canadian expansion of a Phase I/II, Multicenter Study to Evaluate the Safety and Efficacy of a novel, rationally designed, oncology drug candidate in Combination with nab-Paclitaxel (Abraxane®) and Gemcitabine in Patients with Metastatic Pancreatic Cancer.

Scimega launches Canadian expansion of an ongoing Phase 1 / 2 Study of an HSP90 Inhibitor Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.

Scimega launches Canadian expansion of an ongoing Phase 1b, open-label study to assess the safety and tolerability of an orally active, reversible and selective HER2 inhibitor combined with trastuzumab emtansine (TDM1) in HER2+metastatic breast cancer..

See all news...

Upcoming Scimega Events

Clinical Operations in Oncology Trials – West Coast

April 17-18, 2015 in Burlingame, CA

AACR Annual Meeting (American Association for Cancer Research)

April 18-22, 2015 in Philadelphia

Partnerships in Clinical Trials

April 21-24, 2015 in Boston

See all upcoming events...


Latest Podcast

Busting Myths about Canadian Regulatory Review

An interview with Susanne Picard, Founder & President of SPharm
Listen...



Copyright © Scimega Research Inc. 2014. All rights reserved.
Privacy Policy

Oncology CRO   Clinical Trial Monitoring   Clinical Trial Management   Oncology Community